The results showed that ROS1 gene mutations, tumor stage, and the endocrine system diseases history were independent adverse prognostic factors, while KRAS gene mutations were independent prognostic protective factors (Fig. 4A). The gene discussed is ROS1; the disease is endocrine system disorder.